Esperion Therapeutics ESPR Deferred Tax Liabilities
Deferred Tax Liabilities at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxLiabilitiesOther.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's deferred tax liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's deferred tax liabilities?
- Esperion Therapeutics (ESPR) reported deferred tax liabilities of $787K in Q4 2025.
- How has Esperion Therapeutics's deferred tax liabilities changed year-over-year?
- Esperion Therapeutics's deferred tax liabilities decreased by 48.3% year-over-year, from $1.52M to $787K.
- What is the long-term trend for Esperion Therapeutics's deferred tax liabilities?
- Over 5 years (2020 to 2025), Esperion Therapeutics's deferred tax liabilities has grown at a 37.7% compound annual growth rate (CAGR), from $159K to $787K.
- What does deferred tax liabilities mean?
- Future tax obligations from temporary differences — most commonly accelerated tax depreciation that creates higher current tax deductions than book depreciation.